Kintara Therapeutics, Inc. announced that it has completed its merger with Adgero Biopharmaceuticals Holdings, Inc. (Adgero). Commencing August 20, 2020, the combined company will operate as Kintara Therapeutics, Inc. The board of directors of Kintara is now comprised of Robert Hoffman, Laura Johnson, Rob Toth and Saiid Zarrabian, who are current directors of the Company, and John Liatos and Keith Murphy from Adgero.